ArticlePloS one2026
3D CNN-CVAE and LSTM-guided de novo design of rotigotine derivatives targeting dopamine D1 and D3 receptors in restless legs syndrome.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Restless legs syndrome (RLS) is a chronic neurological disorder associated with altered dopaminergic signaling, while long-term dopamine agonist therapy may be limited by augmentation and reduced clinical benefit. This study applied a three-dimensional convolutional neural network conditional variational autoencoder integrated with long short-term memory molecular generation to design rotigotine-derived candidates targeting dopamine D1 and D3 receptors. Fourteen unique derivatives were generated and screened through pocket prediction, molecular docking, interaction profiling, pharmacophore analysis, density functional theory, ADMET prediction, 500 ns molecular dynamics simulations performed in explicit water without a lipid bilayer, and MM/GBSA calculations. Docking protocol validation using DockRMSD yielded RMSD values of 1.009 Å for Mevidalen in the D1 receptor and 1.359 Å for PD-128907 in the D3 receptor, supporting acceptable reproduction of both experimental binding poses. In docking-based ranking, AI Derivative 1 was placed above rotigotine for D1 (-5.744 vs -5.629 kcal/mol) and D3 (-7.934 vs -7.288 kcal/mol) and formed additional hydrogen-bond and hydrophobic contacts; the D1 difference of approximately 0.1 kcal/mol lies within the intrinsic uncertainty of docking scoring functions and is not interpreted as evidence of improved affinity. Docking scores are used throughout as ranking and prioritization metrics rather than quantitative binding free energies. It also exhibited a smaller HOMO-LUMO gap, a higher predicted LD50, and a shift from toxicity class 3 to class 4. Molecular dynamics analyses, including RMSD, RMSF, radius of gyration, solvent-accessible surface area, hydrogen bonding, DCCM, PCA, and free-energy landscapes, are reported as descriptive observations from single non-membrane trajectories and are not used to claim physiological relevance or superior binding stability. MM/GBSA estimates were favorable under the applied computational conditions. AI Derivative 1 therefore represents a computationally prioritized lead requiring experimental validation.
Indexed as
Identifiers
42853897What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.